Apricus Biosciences (APRI) Unit Signs Vitaros Marketing Agreement for Germany
Tweet Send to a Friend
Up)
Apricus Biosciences, Inc. (Nasdaq: APRI) reports that its wholly-owned subsidiary NexMed(USA), Inc. has signed with Sandoz, a division of Novartis (NYSE: NVS), an exclusive collaboration for Germany to market Apricus Bio's Vitaros® drug for the treatment of erectile dysfunction.
Pursuant to the collaboration, Sandoz will pay Apricus Bio up to €21 million – divided into a fixed upfront payment and specific regulatory and commercial milestones – as well as, double digit royalties on net sales. Total upfront and milestone payments represent approximately $28 million based on today's exchange rate.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Pursuant to the collaboration, Sandoz will pay Apricus Bio up to €21 million – divided into a fixed upfront payment and specific regulatory and commercial milestones – as well as, double digit royalties on net sales. Total upfront and milestone payments represent approximately $28 million based on today's exchange rate.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Apricus Bio (APRI) Prices 6M Common Stock Offering
- Brocade (BRCD), A10 Settle Litigation; Brocade to Get $5M Cash, $70M Conv. Note
- News Corp (NWSA) Splits In Two; Announces $500M Buyback Plan
Create E-mail Alert Related Categories
Corporate News, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
